Skip to Content

Join the 'VESIcare' group to help and get support from people like you.

VESIcare News

FDA Approves Supplemental New Drug Application for Myrbetriq (mirabegron) for Use in Combination with Solifenacin Succinate for the Treatment of Overactive Bladder Symptoms

Posted 5 Jun 2018 by Drugs.com

TOKYO, May 7, 2018 /PRNewswire/ – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for the use of mirabegron in combination with the muscarinic antagonist solifenacin succinate for the treatment of overactive bladder (OAB) with symptoms of ...

Overactive Bladder a Common Problem, FDA Says

Posted 19 Jan 2015 by Drugs.com

MONDAY, Jan. 19, 2015 – More than 33 million Americans suffer from overactive bladder, including 40 percent of women and 30 percent of men, the U.S. Food and Drug Administration says. There are numerous approved treatments for the condition, but many people don't seek help because they're embarrassed or don't know about therapy options, according to an agency news release. In people with ...

Ask a Question

Further Information

Related Condition Support Groups

Overactive Bladder, Urinary Incontinence

VESIcare Patient Information at Drugs.com